Health
Johnson & Johnson’s (JNJ) COVID-19 vaccine would have an edge over others without this glitch – AlphaStreet
Johnson & Johnson (NYSE: JNJ) saw its shares climb 2% on Thursday after the company reported positive results from the early-stage trials of its COVID-19 vaccine a day ago. The stock has gained 9% in the past three months and over 8% in the past one year. The companys vaccine candidate has an advantage over its competitors in terms of dosage and storage but this is being hindered by manufacturing issues.
Trial results
On Wednesday, the results from J&Js interim Phase 1/2a trial were published in…
-
Noosa News21 hours agoWoman was watching keepers work when lion attacked, Darling Downs Zoo says
-
Noosa News19 hours agoWorking for someone else made it hard to care for my daughter. So I quit
-
General24 hours agoDeveloper warns wind energy capacity may not be ready by WA coal deadline
-
Business6 hours agoFord CEO makes stunning prediction about artificial intelligence